Saratoga Health & Biotechnology A
(SHPAX)
US Markets Closed
AdChoices
29.40
+0.27
+0.93%
:

Previous Close

29.13

Net Assets

7.59M

Yield

0.00%

Front load

5.75

Expenses

2.60%

Category

Health

Morningstar Risk

Low

Morningstar Rating
AdChoices
Performance
Returns %
Key statistics
  • Composition
  • Performance
  • Top Holdings
  • Top Rated Funds
  • Fund vs. Category
Quarterly Returns
  • Annual

  • SHPAX

  • Category

    • 2013

    • 36.15%

    • -

    • 2012

    • 12.59%

    • -

    • 2011

    • 10.28%

    • -

    • 2010

    • 8.66%

    • -

    • 2013

    • 2012

    • 2011

      • Q1

      • 12.13%

      • 8.41%

      • 5.55%

      • Q2

      • 3.14%

      • -1.73%

      • 9.74%

      • Q3

      • 6.58%

      • 3.87%

      • -11.37%

      • Q4

      • 10.46%

      • 1.74%

      • 7.42%

      Composition
      Sector Weightings
      Equity Investment Style
      The two dimensions of the Fund Style box measure the average size of companies that have been in the FUND, from the top to bottom, and the average valuation characteristics of the FUND's past stock holdings, from left to right.
      • Name

      • % Portfolio Weight

      • Shares Held

      • Change

        • Cardinal Health Inc

        • 5.73

        • 17,300

        • 0

        • Amgen Inc

        • 5.26

        • 8,400

        • 0

        • CR Bard Inc

        • 5.20

        • 7,800

        • 0

        • AstraZeneca PLC ADR

        • 5.12

        • 15,000

        • 0

        • Merck & Co Inc

        • 4.11

        • 15,200

        • 0

        • Becton Dickinson & Co

        • 4.00

        • 7,600

        • 0

        • McKesson Corp

        • 3.94

        • 4,500

        • -1,100

        • Medtronic Inc

        • 3.90

        • 13,600

        • 0

        • Eli Lilly and Co

        • 3.83

        • 13,400

        • 0

        • WellPoint Inc

        • 3.66

        • 7,000

        • 0

        • Name

        • Rating

        • YTD Return %

          • Prudential Jennison Health Sciences A LW

          • ★★★★★
          • 15.57

          • VALIC Company I Health Sciences

          • ★★★★★
          • 16.58

          • Prudential Jennison Health Sciences Z

          • ★★★★★
          • 15.85

          • T. Rowe Price Health Sciences

          • ★★★★★
          • 16.85

          • Franklin Biotechnology Discovery A LW

          • ★★★★
          • 17.52

          • Fidelity Advisor® Health Care A LW

          • ★★★★
          • 18.09

          • Janus Global Life Sciences D

          • ★★★★
          • 17.90

          • Fidelity Advisor® Biotechnology T

          • ★★★★
          • 16.71

          • Prudential Jennison Health Sciences C

          • ★★★★
          • 14.89

          • Fidelity® Select Pharmaceuticals Port

          • ★★★★
          • 13.87

          • Name

          • SHPAX

          • Category

            • Expense Ratio

            • 2.60%

            • 1.45%

            • Net Assets

            • 7.59M

            • 711.24M

            • Dividend Yield

            • 1.87%

            • 0.61

            • Price/Book

            • 2.97

            • 4.82

            • Price/Sales

            • 1.06

            • 3.25

            • Price/Cash Flow

            • 11.31

            • 19.29

            Profile

            Name of Issuer

            Saratoga

            Fund Style

            Open

            Fund Manager

            Mark Oelschlager

            Investment Style

            Large Blend

            The investment seeks long-term capital growth. The fund invests at least 80% of its total assets in equity securities of U.S. and foreign healthcare companies and biotechnology companies, regardless of their stock market value (or "market capitalization"). Equity securities include common stocks, preferred stocks, securities convertible into common stocks and warrants. Under adverse market conditions, it may also make temporary investments in investment grade debt securities. Such investment strategies could result in the Portfolio not achieving its investment objective. The fund is non-diversified.

            Purchase Information

            Initial Purchase 250
            Initial Purchase: IRA NA
            Initial Purchase: AIP NA
            Front load 5.75
            Back Load 5.75

            Inception

            7/15/1999